MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
December 09, 2024 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
November 13, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
November 06, 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte to Participate in Two Upcoming Investor Conferences
October 31, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Cynthia Collins to its Board of Directors
October 15, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
October 11, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
October 10, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 16, 2024 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform...
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
September 05, 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...